Getting Ozempic approved by insurance requires a confirmed type 2 diabetes diagnosis, documentation that cheaper medications haven’t worked well enough, and a prior authorization submitted by your doctor. Most insurers follow a predictable set of requirements, and knowing exactly what they want before you start the process can save you weeks of back-and-forth.
What Insurance Companies Need to See
Ozempic is FDA-approved for three specific uses in adults with type 2 diabetes: improving blood sugar control alongside diet and exercise, reducing the risk of heart attack, stroke, and cardiovascular death in people with established heart disease, and protecting kidney function in people with chronic kidney disease. Insurance companies will only cover it for these indications. If your doctor is prescribing it primarily for weight loss, your claim will almost certainly be denied. The weight loss version of the same drug is sold separately as Wegovy, which has its own coverage criteria and is excluded by many plans entirely.
The core documentation your insurer expects includes a type 2 diabetes diagnosis, recent lab work showing your A1C level, and evidence that you’ve already tried first-line treatments. Most plans look for an A1C above 7%, since clinical trials showed meaningful blood sugar improvement in patients starting at or above that threshold. Ozempic typically lowers A1C by 1.3% to 1.7% depending on the dose, so insurers want to see that your blood sugar is high enough to justify a medication in this class rather than a cheaper alternative.
Step Therapy: The Medications You’ll Need to Try First
Nearly all insurance plans require step therapy before they’ll approve Ozempic. This means you need to show that you tried lower-cost diabetes medications first and that they either didn’t control your blood sugar adequately or caused side effects you couldn’t tolerate. Metformin is the most common requirement. Some plans also expect you to have tried an SGLT2 inhibitor, particularly if you have heart disease or kidney disease.
Your insurer will look for prescription claims in their system showing you filled and used these medications. If you tried metformin years ago and stopped because of stomach problems, your doctor will need to document why it was discontinued. A simple note saying “patient couldn’t tolerate metformin” without specifics is often not enough. The documentation should describe the side effects, how long you took the medication, and what dose you reached before stopping.
If your blood sugar is extremely high, with an A1C above 10% or blood sugars consistently over 300, insurers may actually prefer that your doctor start insulin instead of Ozempic, since the blood sugar reduction needed exceeds what a GLP-1 medication can deliver on its own.
The Prior Authorization Process
Your doctor’s office handles the prior authorization, but you can speed things up by making sure they have everything they need before submitting. Here’s what the request should include:
- Recent A1C results showing your blood sugar is not at goal despite current treatment
- A list of diabetes medications you’ve tried, with dates, doses, and reasons for stopping or switching
- Documented comorbidities such as heart disease, history of heart attack or stroke, peripheral artery disease, or chronic kidney disease (kidney filtration rate below 60 or elevated protein in urine)
- A letter of medical necessity from your prescriber explaining why Ozempic specifically is the right choice over alternatives
Having heart disease or chronic kidney disease can actually strengthen your case, since Ozempic has specific FDA approval for cardiovascular and kidney protection in people with type 2 diabetes. If your doctor can document a history of heart attack, stroke, angina, arterial procedures, or peripheral artery disease, that adds clinical justification beyond blood sugar control alone.
Prior authorization decisions typically take a few days to a couple of weeks. Some insurers have electronic systems that return decisions within 24 to 72 hours. If you haven’t heard back after two weeks, call your insurance company and your doctor’s office to check the status.
What to Do If You’re Denied
A denial isn’t the end of the road. Insurance companies deny prior authorizations for predictable reasons, and each one has a specific fix.
The most common denial reason is “not medically necessary.” This usually means the insurer doesn’t see enough evidence that cheaper options have failed or that your clinical situation requires Ozempic specifically. Start by checking that your doctor’s office used the correct billing and diagnosis codes on the submission. Coding errors are a surprisingly frequent cause of denials that have nothing to do with your actual medical situation. Then ask your doctor to write a detailed letter explaining your treatment history and why alternatives are inadequate.
If the denial says Ozempic is “excluded” from your plan’s formulary, your options are more limited. You can ask your doctor to submit a formulary exception request arguing that the excluded drug is medically necessary for your specific case. Include documentation of all comorbid conditions: diabetes complications, heart disease, kidney disease, or anything else that strengthens the argument that you need this particular medication.
When you submit an appeal, address every specific reason listed in the denial letter. Attach supporting lab results, your medication history, and your doctor’s letter of medical necessity. If your first-level appeal is denied, most plans offer a second-level appeal and then an external review by an independent third party. The external review is often your strongest opportunity, since the reviewer is not employed by your insurance company.
Off-Label Uses Are Rarely Covered
If your doctor wants to prescribe Ozempic for something other than type 2 diabetes, such as PCOS, insulin resistance without a diabetes diagnosis, or weight management, insurance coverage is unlikely. Plans generally will not pay for off-label prescriptions of Ozempic, even if there’s clinical evidence supporting the use. For weight management specifically, your doctor would need to prescribe Wegovy instead, and your plan would need to include obesity medication coverage, which many still do not.
Reducing Your Cost While You Wait
If you have commercial insurance (not Medicare or Medicaid), Novo Nordisk offers a savings card that can significantly reduce your copay. This won’t help if your plan doesn’t cover Ozempic at all, but if your plan covers it with a high copay, the savings card can bring your out-of-pocket cost down substantially. Medicare and Medicaid beneficiaries are not eligible for the savings card.
For people paying entirely out of pocket, Novo Nordisk offers a direct pricing program: $349 per month for the 0.25 mg, 0.5 mg, or 1 mg doses, and $499 per month for the 2 mg dose. These prices are lower than the typical retail cost but still represent a significant monthly expense. Patient assistance programs through the manufacturer may also be available for people who meet income requirements.
How to Give Yourself the Best Chance
Before your doctor submits the prior authorization, call the number on the back of your insurance card and ask for the specific coverage criteria for Ozempic. Many plans will tell you exactly what they need: which medications you must have tried, what A1C threshold they require, and whether cardiovascular or kidney disease qualifies you through a different pathway. Get this in writing if possible, either through your online member portal or by requesting a copy of the plan’s formulary criteria.
Then sit down with your doctor and go through the list point by point. Make sure every requirement is documented in your medical record before the prior authorization is submitted. A complete, well-documented first submission is far more likely to be approved than a thin one followed by an appeal. If your doctor’s office has a staff member who handles prior authorizations regularly, ask to speak with them directly. They often know the common reasons for denial with specific insurers and can preemptively address them.